War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging

Clin Cancer Res. 2022 Jul 15;28(14):2977-2979. doi: 10.1158/1078-0432.CCR-22-1256.

Abstract

In the search for targeting MAPK plus other pathways in NRAS-mutant melanoma, a phase Ib/II trial tested binimetinib plus ribociclib in metastatic melanoma. The response rate in the phase II trial was 19.5%, and the median progression-free survival was 3.7 months. See related article by Schuler et al., p. 3002.

Trial registration: ClinicalTrials.gov NCT04835805 NCT04417621.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aminopyridines
  • Benzimidazoles
  • GTP Phosphohydrolases / genetics
  • Humans
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Melanoma* / mortality
  • Membrane Proteins / genetics
  • Mutation
  • Protein Kinase Inhibitors* / therapeutic use
  • Purines

Substances

  • Aminopyridines
  • Benzimidazoles
  • Membrane Proteins
  • Protein Kinase Inhibitors
  • Purines
  • binimetinib
  • GTP Phosphohydrolases
  • NRAS protein, human
  • ribociclib

Associated data

  • ClinicalTrials.gov/NCT04835805
  • ClinicalTrials.gov/NCT04417621